pharmaphorum6d
Shingrix helps GSK make a solid start in 2023
GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...
Hosted on MSN27d
EMA reviews GSK's new Shingrix syringe for shingles prevention
LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun reviewing a prefilled syringe form of Shingrix, GSK's vaccine for shingles ...
Business Insider27d
GSK announces EMA to review the regulatory application of Shingrix
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix for the prevention of shingles.
PharmiWeb27d
GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...
Pharmabiz25d
EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles
GSK plc announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) ...
FiercePharma18d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Also in vaccines, GSK’s star Shingles vaccine Shingrix saw sales drop 4% at constant exchange rates to 848 million pound sterling ($1.06 billion) in the last three months of 2024. An overall ...